Redeye comments on the pilot order from Saudi Arabia that was announced this morning.
Redeye retains its positive view of Vertiseit following a directed share issue.
Redeye provides its initial take on Scandion Oncology's Q1 2024 report.
Late last night, NoHo Partners updated its financial targets for the strategy period 2025-2027.
Redeye comments on Better Collective’s Q1-results where the company saw slightly higher topline than...
Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Jap...
Redeye updates its view on Flexion Mobile following its Q1 2024 report.
Redeye provides a research update following the Q1 2024 report from Respiratorius.
Redeye updates on Maximum Entertainment following Q1-results which were largely in line with our exp...
Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting...
DKK 650m order over eight years Renovation and expansion of electrical distribution network Strength...
Embellence hosted a CMD on 20 May 2024 New financial targets leverage brand strength We raise '24e-'...
Redeye comments on Thunderful Group’s divestment of the remaining distribution business (Bergsala an...
Redeye comments on the outcome of Alzecure’s rights issue, that secured some SEK39m before issue cos...
Lägre spelaraktivitet pressade kvartalet Mindark minskade omsättningen med 21,9 procent i det första...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
EcoRub (”EcoRub” eller ”Bolaget”) levererar unika material där affärsidén är att förädla återvunnen ...
CirChem (”CirChem” eller ”Bolaget”) har presenterat Bolagets Q1-rapport och fortsätter på den inslag...
Analysguiden sätter motiveraT värde till 33 kr som är baserad på en jämförande värdering.
En investering i Biofrigas Sweden AB (”Biofrigas” eller ”Bolaget”) ger exponering mot den växande ma...
